Forward Pharma A Stock Price To Earning

FWPDelisted Stock  USD 2.56  0.00  0.00%   
Forward Pharma A fundamentals help investors to digest information that contributes to Forward Pharma's financial success or failures. It also enables traders to predict the movement of Forward Stock. The fundamental analysis module provides a way to measure Forward Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Forward Pharma stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Forward Pharma A Company Price To Earning Analysis

Forward Pharma's Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

 = 

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Current Forward Pharma Price To Earning

    
  0.13 X  
Most of Forward Pharma's fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Forward Pharma A is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Competition

Based on the latest financial disclosure, Forward Pharma A has a Price To Earning of 0.13 times. This is 99.5% lower than that of the Biotechnology sector and 97.36% lower than that of the Health Care industry. The price to earning for all United States stocks is 99.55% higher than that of the company.

Forward Price To Earning Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Forward Pharma's direct or indirect competition against its Price To Earning to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Forward Pharma could also be used in its relative valuation, which is a method of valuing Forward Pharma by comparing valuation metrics of similar companies.
Forward Pharma is currently under evaluation in price to earning category among its peers.

Forward Fundamentals

About Forward Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Forward Pharma A's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Forward Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Forward Pharma A based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Forward Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Forward Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Forward Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving against Forward Stock

  0.57MMM 3M Company Fiscal Year End 28th of January 2025 PairCorr
  0.56DD Dupont De Nemours Fiscal Year End 4th of February 2025 PairCorr
  0.52MCD McDonalds Fiscal Year End 3rd of February 2025 PairCorr
  0.49IBM International Business Fiscal Year End 22nd of January 2025 PairCorr
  0.36CAT Caterpillar Fiscal Year End 3rd of February 2025 PairCorr
The ability to find closely correlated positions to Forward Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Forward Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Forward Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Forward Pharma A to buy it.
The correlation of Forward Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Forward Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Forward Pharma A moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Forward Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.

Other Consideration for investing in Forward Stock

If you are still planning to invest in Forward Pharma A check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Forward Pharma's history and understand the potential risks before investing.
Commodity Directory
Find actively traded commodities issued by global exchanges
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios